Brokers Set Expectations for Abeona Therapeutics Inc’s FY2024 Earnings (NASDAQ:ABEO)

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities research analysts at Cantor Fitzgerald cut their FY2024 EPS estimates for Abeona Therapeutics in a report released on Wednesday, April 24th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will earn ($2.38) per share for the year, down from their prior estimate of ($1.86). Cantor Fitzgerald has a “Overweight” rating and a $36.00 price objective on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.83) per share.

Separately, StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday.

Abeona Therapeutics Trading Up 2.2 %

Shares of NASDAQ ABEO opened at $3.26 on Friday. The firm’s 50-day moving average price is $7.37 and its 200-day moving average price is $5.63. Abeona Therapeutics has a 1-year low of $2.83 and a 1-year high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Monday, March 18th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.13).

Institutional Investors Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ABEO. Simplex Trading LLC raised its holdings in shares of Abeona Therapeutics by 1,889.9% in the 3rd quarter. Simplex Trading LLC now owns 14,128 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 13,418 shares during the last quarter. Jump Financial LLC bought a new stake in Abeona Therapeutics in the 4th quarter worth about $199,000. Schonfeld Strategic Advisors LLC bought a new stake in Abeona Therapeutics in the 3rd quarter worth about $648,000. Worth Venture Partners LLC grew its position in Abeona Therapeutics by 76.6% in the 3rd quarter. Worth Venture Partners LLC now owns 281,280 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 121,969 shares in the last quarter. Finally, Barclays PLC grew its position in Abeona Therapeutics by 100.0% in the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company’s stock worth $1,564,000 after purchasing an additional 185,638 shares in the last quarter. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.